Lipoprotein(a) in patients with hepatocellular carcinoma and portal vein thrombosis

• DOI: 10.1007/s40520-016-0653-z
• Publication Date: 2016-11-07T07:58:48Z
• Authors: Giulia Malaguarnera; Vito Emanuele Cat...; Antonio Francaviglia; Michele Malaguarnera; Filippo Drago; Massimo Motta; Saverio Latteri
• Keywords: Male; Venous Thrombosis; 0303 health sciences; Carcinoma, Hepatocellular; Portal Vein; Liver Neoplasms; Statistics as Topic; Ultrasonography, Doppler; Middle Aged; 03 medical and health sciences; Predictive Value of Tests; Humans; Female; Venous thromboembolism ; PVT ; Atherosclerosis; Aged; Lipoprotein(a)

The mechanism for hypercoagulability in malignancy is not entirely understood. Although several studies report contrasting finding about the link between elevated plasma levels of the lipoprotein(a) [Lp(a)] and the possible recurrence of venous thromboembolism, we perform a study to evaluate the impact of the Lp(a) in the development of portal vein thromboembolism (PVT) in patients with HCC.We compared 44 PVT patients with 50 healthy subjects and 50 HCC patients.The comparison between PVT patients and HCC showed in the former the mean value of serum lipoprotein levels was higher than 37.3 mg/dl (p = 0.000). The comparison between PVT versus healthy controls showed that in the former, mean value of serum lipoprotein levels was higher than 75 mg/dl (p = 0.000). The predictive value test of serum lipoprotein(a) on PVT was 0.72 and on HCC was 0.83. The odds ratio of lipoprotein(a) was 9.21 on PVT and 6.33 on HCC.Patients with PVT and HCC showed a statistical significant serum lipoprotein(a) level higher than the subjects with HCC and no PVT or the healthy subject. So we assume a role of lipoprotein(a) as predictor of venous thromboembolism in neoplastic patients.